Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03356054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Study acronym: HOVON 136 NHL
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 10, 2020 (before its estimated January 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jun 2021 to Jan 2023 · Study sites: 17 to 1 · Completion date: Jun 2025 to Feb 2027 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Jun 2021 to Jan 2023
    • Study sites: 17 to 1
    • Completion date: Jun 2025 to Feb 2027
    • Start date changed from estimate of Dec 2017 to Mar 5, 2018
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy and ASCT.
Trial Details
NCT Number NCT03356054
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions DLBCL
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov